Multiomics integration prioritizes potential drug targets for lung cancer
Discover Oncology · 09.06.2026 · 17 (1)
DOI: 10.1007/s12672-026-05415-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Discover Oncology, online erschienen am 09.06.2026. Verfasst von Peize Meng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic Surgery, Precision Medicine Center, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiothoracic Surgery, Precision Medicine Center, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.
- Department of Thoracic Surgery, Shanghai General Hospital, Shanghai Jiao Tong University of Medicine, 650 Songjiang Road, Shanghai, China.
- Department of Thoracic Surgery, Shanghai General Hospital, Shanghai Jiao Tong University of Medicine, 650 Songjiang Road, Shanghai, China. ruanzheng002245@126.com.
- Department of Cardiothoracic Surgery, Precision Medicine Center, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China. xucc0221@163.com.
Zitieren
APA
Meng, P., Zhang, Z., Ruan, Z., & Xu, C. (2026). Multiomics integration prioritizes potential drug targets for lung cancer. Discover Oncology, 17(1). https://doi.org/10.1007/s12672-026-05415-0
Vancouver
Meng P, Zhang Z, Ruan Z, Xu C. Multiomics integration prioritizes potential drug targets for lung cancer. Discover Oncology. 2026;17(1). doi:10.1007/s12672-026-05415-0
BibTeX
@article{Meng2026,
author = {Meng, Peize and Zhang, Zhiping and Ruan, Zheng and Xu, Congcong},
title = {Multiomics integration prioritizes potential drug targets for lung cancer},
journal = {Discover Oncology},
year = {2026},
volume = {17},
number = {1},
doi = {10.1007/s12672-026-05415-0}
}
EUVIMED